<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="174855">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819507</url>
  </required_header>
  <id_info>
    <org_study_id>4590</org_study_id>
    <nct_id>NCT00819507</nct_id>
  </id_info>
  <brief_title>VANOS Cream and Skin Barrier Function</brief_title>
  <official_title>Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicis Pharmaceutical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of short-term therapy using &quot;VANOS
      Cream,&quot; a super-potent topical steroid cream on skin barrier function in patients with
      atopic dermatitis. This cream is already approved for this indication, but the investigators
      will further examine its effects on the skin barrier. This cream is a novel formulation of
      fluocinonide designed to enhance compliance with a cream base, but have the skin barrier
      repair properties of an ointment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema Severity and Area Index</measure>
    <time_frame>2 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transepidermal water loss</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Vanos Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glucocorticoid cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluocinonide</intervention_name>
    <description>Fluocinonide 0.1% cream topical daily for two weeks</description>
    <arm_group_label>Vanos Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AD according to Hanifin-Rajka criteria (see Appendix B)

          -  Age 12 years or older

          -  Must have an Investigator's Global Assessment (IGA) Score of Moderate, Severe, or
             Very Severe (See Appendix C)

          -  Must have failed to achieve adequate disease despite adequate topical or systemic
             therapy

          -  Must be a candidate, according to the principal investigator and standard of care,
             for a super-potent topical steroid course. Subjects that are candidates for
             super-potent topical steroids are defined as subjects whose disease is not adequately
             controlled with medium-potency topical steroids or systemic therapy, including
             phototherapy.

        Exclusion Criteria:

          -  Active skin infection

          -  Hypersensitivity to any ingredients in Vanos cream

          -  Previous use of super-potent topical steroids within 2 weeks of starting study (Class
             I steroid).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maureen Keene</last_name>
    <phone>503-228-7350</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Department of Dermatology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric L Simpson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 11, 2009</lastchanged_date>
  <firstreceived_date>January 8, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Eric Simpson, MD</name_title>
    <organization>Oregon Health &amp; Science university</organization>
  </responsible_party>
  <keyword>Skin barrier</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Effects on skin severity and barrier function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluocinonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
